Person: DALKILIÇ, HÜSEYİN EDİZ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
DALKILIÇ
First Name
HÜSEYİN EDİZ
Name
60 results
Search Results
Now showing 1 - 10 of 60
Publication GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey(Future Medicine, 2021-04-21) Akar, Servet; Kalyoncu, Umut; Dalkılıç, Ediz; Emmüngil, Hakan; Aziz, Ayten; Esen, Yasemin; Koç, Tuba; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; CMF-4757-2022Aim: To evaluate the retention rate of golimumab (GLM) in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (ax-SpA). Materials & methods: Patients had received/were receiving GLM as their first or second biological drug for at least 3 months. We recorded demographic and clinical data, data on drug continuation and disease activity. Patients were classified as biologic-naive and biologic-experienced. Results: The study included 60 RA and 269 ax-SpA patients. At month 24, the retention rates were 67.2 and 57.1% (biologic-naive and biologic-experienced RA) and 74.8 and 80.4% (anti-TNF-naive and -experienced ax-SpA). No significant differences in retention were observed between the biologic-naive and -experienced groups for either disease. Conclusion: The results of this study confirm the effectiveness of GLM in the treatment of RA and axSpA with good retention rates at 2 years in a real-world setting in Turkey.Publication Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability(Springer London, 2021-03-11) Topcu, Atakan; Mursaloğlu, H. Hakan; Yalcınkaya, Yasemin; Karakurt, Sait; Yağız, Burcu; Alaca, Zeynep; Demir, Meryem; Coşkun, Belkıs Nihan; Dalkılıç, Ediz; İnanç, Nevsun; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0003-0298-4157; 0000-0002-0624-1986; 0000-0001-8645-2670; JQW-5031-2023; AAG-7155-2021; CMF-4757-2022Objectives We aim to investigate the relationship between pulmonary function and imaging parameters with symptom-related patient-reported outcome measures (PROs). Method We included 65 patients of rheumatoid arthritis (RA) and connective tissue disease (CTD) with and without interstitial lung disease (ILD) into this cross-sectional study. We evaluated the relationship between FVC, DLco, and PROs and compared to HRCT findings. PROs included visual analogue scale for breathing, modified Borg scale, medical research council dyspnea scale, St. George's respiratory questionnaire (SGRQ), Leicester cough questionnaire, and Short Form 36 quality of life (SF-36 QoL). Results The mean age was 57.4 +/- 9.7 and 61.9% (39/65) of patients had an established ILD. In RA-ILD group, SGRQ score was higher (p < 0.001) and SF-36 physical functioning score was lower (p = 0.02) than CTD-ILD group. In RA group, there was a significant correlation between FVC and SF-36 role functioning/physical score (r = 0.724, p = 0.012). In CTD group, SF-36 general health score was correlated with both FVC (r = 0.441, p = 0.045) and DLco (r = 0.485, p = 0.035), and also SF-36 physical functioning score was correlated with FVC (r = 0.441, p = 0.040). PROs were found to be similar between ILD and non-ILD patients. SF-36 QoL total and SGRQ outcomes were worse in non-ILD group. Conclusions We concluded that PROs could be used to evaluate health-related quality of life (HRQoL) in RA- or CTD-related ILD. The physical health determinants of HRQoL are measurably worse in RA-ILD patients than in CTD patients. But, PROs may not be very helpful in differentiating patients with cough and/or shortness of breath due to ILD or non-ILD causes in RA/CTD.Publication Paraneoplastic arthritis: A multi-centered experience(Bmj Publishing Group, 2013-06-01) Kısacık, B.; Onat, A. M.; Kaşifoğlu, T.; Pehlivan, Y.; Pamuk, O. N.; Dönmez, S.; Bilge, S. Y.; Yılmaz, S.; Erdern, H.; Mercan, R.; Öztürk, M. A.; Bes, C.; Soy, M.; Erten, S.; Çobankara, V.; Şenel, S.; Öner, F. A.; Direskeneli, H.; Yilmaz, S.; Kul, S.; Çetin, G. Y.; Sayarlioğlu, M.; Dalkilic, E.; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.Publication Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu Arteritis in a genome-wide association study(Wiley, 2015-05-01) Renauer, Paul A.; Saruhan-Direskeneli, Guher; Coit, Patrick; Adler, Adam; Aksu, Kenan; Keser, Gökhan; Alibaz-Öner, Fatma; Aydın, Sibel Z.; Kamali, Sevil; İnanç, Murat; Carette, Simon; Cuthbertson, David; Hoffman, Gary S.; Akar, Servet; Önen, Fatoş; Akkoç, Nurullah; Khalidi, Nader A.; Koening, Curry; Karadağ, Ömer; Kiraz, Sedat; Langford, Carol A.; Maksimowicz-McKinnon, Kathleen; McAlear, Carol A.; Özbalkan, Zeynep; Ateş, Aşkın; Karaaslan, Yaşar; Düzgün, Nursen; Monach, Paul A.; Özer, Hüseyin T. E.; Erken, Eren; Öztürk, Mehmet A.; Yazıcı, Ayten; Cefle, Ayşe; Onat, Ahmet Mesut; Kısacık, Bünyamin; Pagnoux, Christian; Kaşifoğlu, Timuçin; Seyahi, Emire; Fresko, İzzet; Seo, Philip; Sreih, Antoine G.; Warrington, Kenneth J.; Ytterberg, Steven R.; Cobankara, Veli; Cunninghame-Graham, Deborah S.; Vyse, Timothy J.; Pamuk, Ömer N.; Tunç, S. Ercan; Dalkılıç, Ediz; Bıçakçıgil, Müge; Yentur, Sibel P.; Wren, Jonathan D.; Merkel, Peter A.; Direskeneli, Haner; Sawalha, Amr H.; DALKILIÇ, HÜSEYİN EDİZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; CMF-4757-2022Objective. Takayasu arteritis is a rare large vessel vasculitis with incompletely understood etiology. This study was undertaken to perform the first unbiased genome-wide association analysis of Takayasu arteritis.Methods. Two independent cohorts of patients with Takayasu arteritis from Turkey and North America were included in our study. The Turkish cohort consisted of 559 patients and 489 controls, and the North American cohort consisted of 134 patients and 1,047 controls of European ancestry. Genotyping was performed using the Omni1-Quad and Omni2.5 genotyping arrays. Genotyping data were subjected to rigorous quality control measures and subsequently analyzed to discover genetic susceptibility loci for Takayasu arteritis.Results. We identified genetic susceptibility loci for Takayasu arteritis with a genome-wide level of significance in IL6 (rs2069837) (odds ratio [OR] 2.07, P = 6.70 x 10(-9)), RPS9/LILRB3 (rs11666543) (OR 1.65, P = 2.34 x 10(-8)), and an intergenic locus on chromosome 21q22 (rs2836878) (OR 1.79, P = 3.62 x 10(-10)). The genetic susceptibility locus in RPS9/LILRB3 lies within the leukocyte receptor complex gene cluster on chromosome 19q13.4, and the disease risk variant in this locus correlates with reduced expression of multiple genes including the inhibitory leukocyte immunoglobulin-like receptor gene LILRB3 (P = 2.29 x 10(-8)). In addition, we identified candidate susceptibility genes with suggestive levels of association (P < 1 x 10(-5)) with Takayasu arteritis, including PCSK5, LILRA3, PPM1G/NRBP1, and PTK2B.Conclusion. Our findings indicate novel genetic susceptibility loci for Takayasu arteritis and uncover potentially important aspects of the pathophysiology of this form of vasculitis.Publication The relationship between formal education level and delay in diagnosis and disease activity in patients with rheumatoid arthritis(BMJ Publishing Group, 2015-06-01) Öksüz, Mustafa Ferhat; YıIdırım, F.; Şahin, Bilgehan Ahmet; Göçken, Abdulkadir; Tufan, Ayşe Nur; Oruçoğlu, Nurdan; Dalkılıç, Ediz; Pehlivan, Yavuz; Öksüz, Mustafa Ferhat; YıIdırım, F.; ŞAHİN, AHMET BİLGEHAN; Göçken, Abdulkadir; Tufan, Ayşe Nur; Oruçoğlu, Nurdan; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Uludağ Üniversitesi/Tıp Fakültesi; 0000-0002-7846-0870; 0000-0002-8613-5373; D-2589-2017; AAM-4927-2020; AAG-8227-2021; JXF-7598-2024; EHU-6506-2022; CQX-7131-2022; GHE-4236-2022; CMF-4757-2022Publication Cigarette smoking does not affect treatment response to tofacitinib in rheumatoid arthritis(Wiley, 2018-09-01) Karataş, Ahmet; Öz, Burak; Dalkılıç, Ediz; Can, Gerçek; Pehlivan, Yavuz; Şenel, Soner; Yazıcı, Ayten; İnanç, Nevsun; Ertürk, Zeynep; Cefle, Ayşe; Akar, Servet; Koca, Süleyman Serdar; Birlik, Merih; Önen, Fatoş; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Bölümü; CMF-4757-2022; AAG-8227-2021Publication Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study(Springer London, 2021-08-23) Karadağ, Ömer; Dalkılıç, Ediz; Ayan, Gizem; Küçükşahin, Orhan; Kaşifoğlu, Timuçin; Yılmaz, Neslihan; Koca, Süleyman Serdar; Yazısız, Veli; Erten, Pınar Talu; Sayarlıoğlu, Mehmet; Terzioğlu, Mustafa Ender; Erten, Şükran; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; CMF-4757-2022Objectives To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment.Method One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9.Results A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 +/- 11.1 years and 6.9 +/- 6.5 years, respectively. The most commonly used TNF alpha inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit.Conclusions The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment.Publication Clinical features of takayasu's arteritis from an inception cohort: Early disease is characterized by 'systemic inflammation'(Wiley, 2016-10-01) Alibaz-Öner, Fatma; Ünal, Ali Uğur; Onat, Ahmet Mesut; Kısacık, Bünyamin; Zengin, Orhan; Karadağ, Ömer; Erden, Abdulsamet; Yarkan, Handan; Akar, Servet; Yıldız, Fatih; Erken, Eren; Özer, Hüseyin; Omma, Ahmet; Özbalkan, Zeynep; Karaaslan, Yaşar; Bes, Cemal; Öner, Sibel Yılmaz; Kanıtez, Nilüfer Alpay; Bayndır, Özün; Yavuz, Şule; Düzgün, Nursen; Tufan, Ayşe Nur; Dalkılıç, Ediz; Yoshifuji, Hajime; Tufan, Abdurrahman; Akyol, Lütfi; Öztürk, Mehmet Akif; Sayarlıoğlu, Mehmet; Aksu, Kenan; Keser, Gökhan; Kiraz, Sedat; Pamuk, Ömer Nuri; Önen, Fatoş; Direskeneli, Haner; Tufan, Ayse Nur; DALKILIÇ, HÜSEYİN EDİZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; GHE-4236-2022; CMF-4757-2022Publication Disease activity indices and body mass index: Cross-sectional analysis of a large psoriatic arthritis cohort(Wiley, 2015-10-01) Kalyoncu, Umut; Bayndar, Ozun; Yilmazer, Barış; Dalkılıç, Hüseyin Ediz; Aksu, Kenan; Öksüz, Mustafa Ferhat; Tarhan, E. Figen; Can, Meryem; Küçükşahin, Orhan; Kimyon, Gezmiş; Akyol, Lütfi; Onat, Ahmet Mesut; Kısacık, Bünyamin; Erden, Abdülsamet; Omma, Ahmet; Bakırlı, Duygu Ersözlü; Özişler, Cem; Gönüllü, Emel; Pehlevan, Seval; Solmaz, Dilek; Çınar, Muhammet; Çetin, Gözde; Tufan, Abdurrahman; Tufan, Müge Aydın; Kılıç, Levent; Erten, Şükran; Kaşifoğlu, Timuçin; Kobak, Şenol; Şenel, Soner; Akar, Servet; Özgen, Metin; Kasapoğlu-Günal, Esen; Yazısız, Veli; Yılmaz, Sedat; Dönmez, Salim; Doğan, İsmail; Köseoğlu, Hamide Kart; Erbasan, Funda; Yıldız, Fatih; Beş, Cemal; Balkarlı, Ayşe; Şahin, Ali; Mercan, Rıdvan; Arslan, Fatoş; Doğru, Atalay; Pay, Salih; Yavuz, Şule; Çakır, Necati; Kabasakal, Yasemin; Aydın, Sibel Z.; DALKILIÇ, HÜSEYİN EDİZ; CMF-4757-2022Publication Interim analysis of baseline characteristics and preferences of administration route of rheumatoid arthritis patients who are bio-naive or switched between advanced ra treatments; a multicenter, prospective, observational study(Wiley, 2018-09-01) Direskeneli, Haner; Karadağ, Ömer; Ateş, Aşkın; Tufan, Abdurrahman; İnanç, Nevsun; Koca, Süleyman Serdar; Çetin, Gözde Yıldırım; Akar, Servet; Çınar, Muhammet; Yılmaz, Sedat; Yılmaz, Neslihan; Dalkılıç, Ediz; Beş, Cemal; Özbalkan, Zeynep; Yılmazer, Bariş; Şahin, Ali; Ersözlü, Emine Duygu; Tezcan, Mehmet Engin; Şen, Nesrin; Keser, Gökhan; Tansoker, İlkan; Hacıbedel, Fatma Başak; Helvacıoğlu, Kerem; Günay, Levent Mert; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CMF-4757-2022